Citigroup Inc. Begins Coverage on Abeona Therapeutics Inc. (ABEO)

Citigroup Inc. began coverage on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research report sent to investors on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $32.00 target price on the biopharmaceutical company’s stock.

A number of other research analysts have also commented on the stock. BidaskClub upgraded shares of Abeona Therapeutics from a buy rating to a strong-buy rating in a research report on Wednesday, July 12th. Cantor Fitzgerald set a $21.00 price target on shares of Abeona Therapeutics and gave the company a buy rating in a research report on Tuesday, July 18th. Maxim Group set a $17.00 price target on shares of Abeona Therapeutics and gave the company a buy rating in a research report on Tuesday, August 29th. Zacks Investment Research upgraded shares of Abeona Therapeutics from a hold rating to a buy rating and set a $10.00 price target for the company in a research report on Tuesday, July 11th. Finally, HC Wainwright restated a buy rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday, August 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $21.44.

Abeona Therapeutics (ABEO) traded down 2.79% during midday trading on Tuesday, reaching $17.06. The company’s stock had a trading volume of 244,999 shares. The company’s market cap is $687.30 million. Abeona Therapeutics has a 12 month low of $4.05 and a 12 month high of $22.75. The stock has a 50-day moving average price of $15.16 and a 200 day moving average price of $8.64.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.21 million. Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. Analysts expect that Abeona Therapeutics will post ($0.70) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Citigroup Inc. Begins Coverage on Abeona Therapeutics Inc. (ABEO)” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://sportsperspectives.com/2017/10/13/citigroup-inc-begins-coverage-on-abeona-therapeutics-inc-abeo.html.

A number of large investors have recently made changes to their positions in ABEO. Family Management Corp purchased a new position in Abeona Therapeutics in the first quarter worth $120,000. State of Wisconsin Investment Board purchased a new position in Abeona Therapeutics in the second quarter worth $122,000. Rhumbline Advisers purchased a new position in Abeona Therapeutics in the second quarter worth $190,000. Bank of New York Mellon Corp grew its position in Abeona Therapeutics by 125.8% in the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 23,358 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. purchased a new position in Abeona Therapeutics in the second quarter worth $264,000. Institutional investors own 38.38% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply